JPMorgan downgraded Neumora Therapeutics (NMRA) to Underweight from Neutral without a price target The company’s Phase 3 KOASTAL-1 trial evaluating navacaprant as a monotherapy treatment in major depressive disorder failed to hit its primary endpoint or key secondary endpoint earlier this year, the analyst tells investors in a research note. The firm believes Neumora shares will continue to underperform peers into the Phase 3 KOASTAL-2 and KOASTAL-3 trial readouts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics Faces Challenges as It Transitions to Full Public Company Compliance
- Neumora Therapeutics’ Earnings Call Highlights Promising Pipeline
- Neumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215
- Promising Developments and Pipeline Progress Drive Buy Rating for Neumora Therapeutics
- Neumora Therapeutics Reports Q2 2025 Financial Results